
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitiv... MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0544 | -5.44272136068 | 0.9995 | 1.08 | 0.8 | 231635 | 0.95644047 | CS |
4 | -0.2149 | -18.525862069 | 1.16 | 1.2 | 0.8 | 195418 | 1.05074036 | CS |
12 | -0.1986 | -17.3646935385 | 1.1437 | 1.5 | 0.8 | 311071 | 1.16674268 | CS |
26 | -0.5349 | -36.1418918919 | 1.48 | 2.5591 | 0.8 | 908998 | 1.54857366 | CS |
52 | -0.5649 | -37.4105960265 | 1.51 | 5.01 | 0.51 | 1868337 | 2.91024064 | CS |
156 | -6.0549 | -86.4985714286 | 7 | 7.9799 | 0.51 | 1299613 | 2.83752691 | CS |
260 | -6.0549 | -86.4985714286 | 7 | 7.9799 | 0.51 | 1299613 | 2.83752691 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions